AbD Serotec receives large research antibody order from Proteomika

MorphoSys's AbD Serotec business unit has received a multiple research antibody order from biomarker discovery specialist Proteomika.

Proteomika, based in Spain, has ordered novel HuCAL-based research antibodies against a broad range of target molecules in addition to the production of antigen material at AbD Serotec. AbD Serotec will apply MorphoSys's HuCAL GOLD antibody technology and the proprietary Antigen Expression System AgX. The order ranks Proteomika among the largest customers for custom monoclonals services provided by AbD Serotec. Financial details of the agreement were not disclosed.

Proteomika was established in 2002 as a subsidiary of genomics company Progenika Biopharma with the objective of exploiting advances in biomarker research for the development of diagnostic and prognostic products. The company has established research collaborations with numerous pharmaceutical and biotechnology companies aimed at the discovery and validation of non-invasive diagnostic and pharmacoproteomics markers as well as identifying novel therapeutic targets. Proteomika is actively involved in in-house discovery projects at the bioGUNE Research Institute in cancer and other disease areas.

Dr Laureano Simon, chief executive officer of Proteomika, said "The fast turn around in antibody production offered by AbD Serotec, together with the high quality of the resulting antibodies, will help accelerate the process of biomarker identification and validation, allowing Proteomika to bring new diagnostic and prognostic tools for human diseases to the market in the shortest possible timeframe."

MorphoSys ceo Dr Simon Moroney. "This order is one of the largest generated by AbD Serotec, and highlights the advantage of our HuCAL technology in bespoke proteomics applications."